瑞士诺华制药公司在印度打输专利官司

India\'s Supreme Court has rejected a patent bid by Swiss drug maker Novartis for a cancer drug.

In a landmark ruling Monday, the court dismissed patent protection to an updated version of the drug Glivec. 

The ruling is a precedent that prevents international pharmaceutical companies from obtaining fresh patents in India on updated versions of existing drugs.

India\'s law prevents companies from seeking patents for making only slight modifications to an existing drug.

The Supreme Court decided Monday the updated Glivec did not satisfy the "novelty" aspect required by Indian patent law.

The ruling is a victory for India\'s multi-billion-dollar generic drug industry that provides cheap medicines to millions around the world.

Novartis has been fighting since 2006 to win a patent for the amended form of Glivec.

星期一，印度最高法院做出具有里程碑意义的裁决，拒绝给予升级版Glivec专利保护。

这项裁决将成为一项先例，防止国际制药公司就既有药品的升级版从印度获得新专利保护。

根据印度法律，公司不得为仅做细微变动的既有药品申请专利。

印度最高法院星期一裁定，升级版Glivec不具备印度专利法所要求的创新性质。

这项裁决是印度拥有巨额利润的非专利药制造业界的胜利，这一产业为世界各地数以百万计的人提供廉价药。